IL309483A - Treatment of hypertension with isoform-regulated factor 2 inhibitors A3 solute carrier family 9 (SLC9A3R2) - Google Patents

Treatment of hypertension with isoform-regulated factor 2 inhibitors A3 solute carrier family 9 (SLC9A3R2)

Info

Publication number
IL309483A
IL309483A IL309483A IL30948323A IL309483A IL 309483 A IL309483 A IL 309483A IL 309483 A IL309483 A IL 309483A IL 30948323 A IL30948323 A IL 30948323A IL 309483 A IL309483 A IL 309483A
Authority
IL
Israel
Prior art keywords
slc9a3r2
isoform
hypertension
inhibitors
treatment
Prior art date
Application number
IL309483A
Other languages
English (en)
Hebrew (he)
Inventor
Manuel Allen Revez Ferreira
Joshua Backman
Alexander Li
Luca Andrea Lotta
Goncalo Abecasis
Aris Baras
Jonas Nielsen
Original Assignee
Regeneron Pharma
Manuel Allen Revez Ferreira
Joshua Backman
Alexander Li
Luca Andrea Lotta
Goncalo Abecasis
Aris Baras
Jonas Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Manuel Allen Revez Ferreira, Joshua Backman, Alexander Li, Luca Andrea Lotta, Goncalo Abecasis, Aris Baras, Jonas Nielsen filed Critical Regeneron Pharma
Publication of IL309483A publication Critical patent/IL309483A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL309483A 2021-07-02 2022-06-30 Treatment of hypertension with isoform-regulated factor 2 inhibitors A3 solute carrier family 9 (SLC9A3R2) IL309483A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163217909P 2021-07-02 2021-07-02
US202163221031P 2021-07-13 2021-07-13
PCT/US2022/035712 WO2023278694A1 (en) 2021-07-02 2022-06-30 Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors

Publications (1)

Publication Number Publication Date
IL309483A true IL309483A (en) 2024-02-01

Family

ID=82703151

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309483A IL309483A (en) 2021-07-02 2022-06-30 Treatment of hypertension with isoform-regulated factor 2 inhibitors A3 solute carrier family 9 (SLC9A3R2)

Country Status (8)

Country Link
US (1) US20230027007A1 (https=)
EP (1) EP4363581A1 (https=)
JP (1) JP2024524374A (https=)
KR (1) KR20240029763A (https=)
AU (1) AU2022303368A1 (https=)
CA (1) CA3222828A1 (https=)
IL (1) IL309483A (https=)
WO (1) WO2023278694A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3093351B1 (en) * 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
CN115003800A (zh) * 2019-08-28 2022-09-02 安斯泰来再生医药协会 治疗血管疾病的方法

Also Published As

Publication number Publication date
JP2024524374A (ja) 2024-07-05
US20230027007A1 (en) 2023-01-26
CA3222828A1 (en) 2023-01-05
KR20240029763A (ko) 2024-03-06
EP4363581A1 (en) 2024-05-08
AU2022303368A1 (en) 2023-12-21
WO2023278694A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
IL308195A (en) RAS inhibitors for cancer treatment
IL288395A (en) Mat2a tricyclic inhibitors and methods for use in cancer therapy
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020551464A1 (en) Cd73 inhibitors
IL320739A (en) rock2 inhibitors
EA202192426A1 (ru) Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких
IL316829A (en) Menin-MLL inhibitors for cancer treatment
IL316616A (en) ROCK2 inhibitors
IL320191A (en) Solute carrier family 6A member 19 inhibitors (SLC6A19) and methods of using them
LT4447683T (lt) Izoksazolinkarboksamido panaudojimas daigų formavimosi slopinimui
SG11202105577TA (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
MX2022000782A (es) Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
IL309483A (en) Treatment of hypertension with isoform-regulated factor 2 inhibitors A3 solute carrier family 9 (SLC9A3R2)
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
HK40110397A (en) Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors
SMT202500486T1 (it) Inibitori del percorso di jak1 per il trattamento di prurigo nodularis
IL318512A (en) Methods for treating hypertension using focused, transcranial ultrasound
IL290540A (en) Compounds suitable for the treatment and prevention of muscle wasting and other conditions
EP3797776C0 (en) CDK4/6 INHIBITORS FOR THE TREATMENT OF PSORIASIS
IL286308A (en) Treatment of hyperglycemia with inhibitors of the solute carrier family 39 member 5 (slc39a5)
EP4419089A4 (en) HYPOXIA-INDUCIBLE FACTOR 2-(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER
IL311027A (en) Il-13 inhibitors for the treatment of prurigo nodularis
IL309480A (en) Asthma treatment methods with solute carrier inhibitors for family 27 members 3 (SLC27A3)
EP3952868C0 (en) COMBINATIONS OF NITAZOXANIDE OR TIZOXANIDE AND ELAFIBRANOR FOR THE TREATMENT OF INFLAMMATION ASSOCIATED WITH PRIMARY SCLEROSING CHOLANGITIS OR PRIMARY BILIARY CHOLANGITIS
IL326826A (en) Solute carrier family 6A member 19 (SLC6A19) inhibitors and methods of using them